MUC16 and lung cancer: 0.48%, 0.25%, 0.21%, 0.16% and 1% were diagnosed with lower GI cancer, uterine cancer, lung cancer, pancreatic cancer and other cancers, respectively, within 1 year of CA125 testing (Table 2).